Boyd B - Search Results

1

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, Canil CM, Winquist E, Hotte SJ, North SA, Heng DYC, Macfarlane RJ, Venner PM, Kapoor A, Hansen AR, Eigl BJ, Czaykowski P, Boyd B, Wang L, Basappa NS. Bjarnason GA, et al. Among authors: boyd b. Eur J Cancer. 2019 Feb;108:69-77. doi: 10.1016/j.ejca.2018.12.006. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30648632 Free article. Clinical Trial.

2

Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation.

Kaminskas LM, McLeod VM, Porter CJ, Boyd BJ. Kaminskas LM, et al. Mol Pharm. 2012 Mar 5;9(3):355-73. doi: 10.1021/mp2005966. Epub 2012 Jan 26. Mol Pharm. 2012. PMID: 22250750 Review.

3

Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.

Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJ. Boyd BJ, et al. Mol Pharm. 2006 Sep-Oct;3(5):614-27. doi: 10.1021/mp060032e. Mol Pharm. 2006. PMID: 17009860

4

Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.

Kaminskas LM, Boyd BJ, Karellas P, Henderson SA, Giannis MP, Krippner GY, Porter CJ. Kaminskas LM, et al. Mol Pharm. 2007 Nov-Dec;4(6):949-61. doi: 10.1021/mp070047s. Epub 2007 Oct 23. Mol Pharm. 2007. PMID: 17953445

5

The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.

Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Kelly B, Porter CJ. Kaminskas LM, et al. Among authors: boyd bj. Mol Pharm. 2008 May-Jun;5(3):449-63. doi: 10.1021/mp7001208. Epub 2008 Apr 5. Mol Pharm. 2008. PMID: 18393438

6

Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.

Kaminskas LM, Kelly BD, McLeod VM, Boyd BJ, Krippner GY, Williams ED, Porter CJ. Kaminskas LM, et al. Mol Pharm. 2009 Jul-Aug;6(4):1190-204. doi: 10.1021/mp900049a. Mol Pharm. 2009. PMID: 19453158

7

Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.

Kaminskas LM, Kelly BD, McLeod VM, Sberna G, Boyd BJ, Owen DJ, Porter CJ. Kaminskas LM, et al. Mol Pharm. 2011 Apr 4;8(2):338-49. doi: 10.1021/mp1001872. Epub 2011 Jan 21. Mol Pharm. 2011. PMID: 21171585

8

Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.

Kaminskas LM, Kelly BD, McLeod VM, Sberna G, Owen DJ, Boyd BJ, Porter CJ. Kaminskas LM, et al. J Control Release. 2011 Jun 10;152(2):241-8. doi: 10.1016/j.jconrel.2011.02.005. Epub 2011 Feb 21. J Control Release. 2011. PMID: 21315119

9

A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.

Kaminskas LM, McLeod VM, Kelly BD, Sberna G, Boyd BJ, Williamson M, Owen DJ, Porter CJ. Kaminskas LM, et al. Nanomedicine. 2012 Jan;8(1):103-11. doi: 10.1016/j.nano.2011.05.013. Epub 2011 Jun 23. Nanomedicine. 2012. PMID: 21704192

10

Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties.

Kaminskas LM, Boyd BJ, Porter CJ. Kaminskas LM, et al. Nanomedicine (Lond). 2011 Aug;6(6):1063-84. doi: 10.2217/nnm.11.67. Nanomedicine (Lond). 2011. PMID: 21955077 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

734 results

Search Page